A study utilizing data from the National Institutes of Health’s All of Us Research Program has identified thousands of previously unknown variants in 16 genes that influence how individuals respond to prescription medications. The research examined genetic information from nearly 100,000 American participants, representing more diverse ancestries than previous pharmacogenomic studies. Findings indicated that all study participants carried at least one variant in the studied genes, and approximately one in four had used medications that could be affected by these genetic differences.
The research, published in Science Translational Medicine, advances the field of pharmacogenomics—the study of how genetic variations affect drug metabolism and efficacy. The identified variants influence responses to various medication classes including antidepressants, cholesterol-lowering drugs, chemotherapy agents, and anticoagulants. Genetic differences can result in altered drug metabolism requiring dose adjustments, increased susceptibility to side effects, or reduced medication effectiveness. Researchers emphasized that genetic factors represent one important explanation for why patients respond differently to the same medications.
The broader applicability of these findings to diverse populations addresses a significant gap in previous research. The All of Us program’s commitment to recruiting participants from varied genetic backgrounds enabled discovery of variants not detected in earlier studies using different genomic databases. Experts note this inclusive approach is crucial for preventing new precision medicine technologies from inadvertently creating healthcare disparities.
Implementation of these findings into clinical practice faces several obstacles. Many patients lack sequenced genomes, physicians may have limited awareness of pharmacogenetic implications for their prescriptions, and the complexity of multiple interacting variants complicates clinical decision-making. Additionally, the All of Us program faces substantial funding challenges that could limit future research capacity. The program’s primary funding mechanism through the 21st Century Cures Act will expire in the 2027 fiscal year, and anticipated Congressional appropriations represent an 80% reduction from 2023 funding levels. These budget constraints have forced the program to reduce patient recruitment activities and discontinue offering participants access to their genetic test results. Pediatric enrollment, which began in 2023, currently includes approximately 5,000 children, though this data remains unavailable to researchers pending sufficient funding and program expansion.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI